A Patient with Chronic Hepatitis C and a History of Abuse of Analeptic Drugs, Who Showed Hallucination and Delusion with Interferon Administration.

Muraoka, Haruo; Sanefuji, T; Keida, Ryuji; Tsuji, Riko; Abe, Hirohiko; Uchimura, Yasuyo; Sata, Michio; Tanikawa, Kyuic; Nose, Iwao; Uchimura, N.; Nakazawa, Yoichi

doi:10.2739/kurumemedj.43.73

Cited by 6 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three cases of psychotic episodes have been described after 4–12 weeks of IFN-α treatment [62]. Manic and delirious episodes, with persecution and complex thought disorder, have also been described after several weeks or months of IFN-α therapy [33,51,62,64,66].…”

Section: Resultsmentioning

confidence: 99%

Psychiatric side effects of interferon-β in multiple sclerosis

Goeb¹,

Even

Guillaume

et al. 2006

Eur. psychiatr.

View full text Add to dashboard Cite

Psychiatric disorders, especially depression, are frequent in patients with multiple sclerosis (MS). They are attributed both to the psychosocial impact of a chronic, usually progressive, disabling illness and to cerebral demyelination. Besides, drugs such as corticosteroids and possibly interferon (IFN) may also have depressogenic effects. Major depressive disorders and/or suicidal ideation are a major concern and efforts to identify and minimize these reactions are of much importance. Psychiatric side effects, particularly depression, are widely reported with IFN-alpha and have been suspected with IFN-beta but are not yet fully established. Our review of the literature revealed that most studies discard an association between IFN-beta and depression or suicide. However, few patients, especially those with a history of depression, might be at higher risk for depression when treated with IFN-beta. Overall, considering the uncertainty of a link between IFN-beta and depression and/or suicide, as well as the complete remission of psychiatric complications after IFN discontinuation and/or antidepressant treatment, physicians should closely monitor the psychiatric status of patients, but should not refrain from including them in IFN-beta treatment programs, even when they have past or present depression.

show abstract

Section: Resultsmentioning

confidence: 99%

Psychiatric side effects of interferon-β in multiple sclerosis

Goeb¹,

Even

Guillaume

et al. 2006

Eur. psychiatr.

View full text Add to dashboard Cite

show abstract

“…In the second patient, IFN therapy was associated with emergence of PTSD symptoms in a patient with a history of trauma. In patients with a history of substance abuse disorder, flashbacks have been reported following treatment with natural IFN alfa (77).…”

Section: Isolated Ifn-induced Psychiatric Symptomsmentioning

confidence: 99%

Neuropsychiatric Complications of Interferons: Classification, Neurochemical Bases, and Management

Malek-Ahmadi¹,

Hilsabeck²

2007

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

show abstract

“…The high rate of psychiatric comorbidity with increased risk of severe psychiatric side-effects might further complicate IFN-α treatment further (Renault and Hoofnagle, 1989;Muraoka et al, 1996). There are a few case reports of psychotic episodes in drug users during IFN-α treatment (Renault et al, 1987;McDonald et al, 1987;Hendrik, 1994;Muraoka et al, 1996) and these have been interpreted as flash-back psychosis, or delirium, due to previous drug abuse.…”

Section: Introductionmentioning

confidence: 95%

“…There are a few case reports of psychotic episodes in drug users during IFN-α treatment (Renault et al, 1987;McDonald et al, 1987;Hendrik, 1994;Muraoka et al, 1996) and these have been interpreted as flash-back psychosis, or delirium, due to previous drug abuse. However, a recent study has shown that patients with hepatitis C and mood or anxiety disorders were not more likely to develop psychiatric side-effects compared to normal controls when receiving IFN-α treatment, although these patients are thought of as contraindicated for IFN-α treatment (Pariente et al, 1999).…”

Section: Introductionmentioning

confidence: 97%

“…Interferon-alpha (IFN-α) is the pharmacological treatment of choice in the treatment of hepatitis C. Various gastrointestinal, respiratory, dermatological and haematological symptoms may be experienced by patients undergoing IFN-α treatment (Renault et al, 1987;Malek-Ahmadi, 2001). In addition, psychiatric sideeffects, such as the development of depression, mania, irritability, changes in personality, hallucinations and delirium, can manifest themselves (Renault and Hoofnagle, 1989;Muraoka et al, 1996).…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Major depressive disorder with psychotic features induced by interferon-α treatment for hepatitis C in a polydrug abuser

et al. 2005

View full text Add to dashboard Cite

Infectious diseases, especially hepatitis C, are prevalent among drug abusers. Interferon-alpha (IFN-alpha) is the pharmacological treatment of choice for this condition. Patients being treated with IFN-alpha can be expected to experience such psychiatric side-effects as development of depression, mania, irritability, changes in personality, hallucinations or delirium. In addition, certain patients are considered to be at greater risk of developing neuropsychiatric side-effects. Individuals meeting the following criteria are particularly vulnerable: over 40 years of age; having central nervous system abnormalities; a previous neurological or psychiatric history; a past familial psychiatric history; use of narcotics or having alcohol or substance use disorders; being HIV-positive; coadministration of other cytokines; receiving high doses of IFN-alpha (> 6 million units). We report the case of a 29-year-old patient with chronic non-active hepatitis C, a previous psychiatric history of polydrug abuse (cannabis, heroin and illegal use of the psychotropic drug biperiden) and anxiety disorder. Two weeks after the initiation of IFN-alpha treatment, he developed fatigue, sleeplessness and persecutory delusions. The patient responded partially to the discontinuation of the IFN-alpha treatment. Due to the presence of three risk factors in this patient, he was considered to belong to the group of patients being 'at high risk' of developing neuropsychiatric side-effects. This is the first case report of major depressive disorder with psychotic features in such a 'high-risk patient'. This case report may prompt other research by showing the importance of the close monitoring, and the prevention of the progression of IFN-alpha-related psychiatric disorders in 'a high-risk patient'.

show abstract

A Patient with Chronic Hepatitis C and a History of Abuse of Analeptic Drugs, Who Showed Hallucination and Delusion with Interferon Administration.

Cited by 6 publications

References 2 publications

Psychiatric side effects of interferon-β in multiple sclerosis

Psychiatric side effects of interferon-β in multiple sclerosis

Neuropsychiatric Complications of Interferons: Classification, Neurochemical Bases, and Management

Major depressive disorder with psychotic features induced by interferon-α treatment for hepatitis C in a polydrug abuser

Contact Info

Product

Resources

About